Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Buys 6,000 Shares

by · The Markets Daily

Anixa Biosciences, Inc. (NASDAQ:ANIX – Get Free Report) Director Lewis H. Titterton, Jr. acquired 6,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was acquired at an average price of $2.59 per share, with a total value of $15,540.00. Following the completion of the transaction, the director now directly owns 928,334 shares of the company’s stock, valued at approximately $2,404,385.06. This represents a 0.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anixa Biosciences Trading Up 7.5 %

Shares of NASDAQ ANIX traded up $0.21 during mid-day trading on Wednesday, reaching $3.02. The company had a trading volume of 200,861 shares, compared to its average volume of 138,421. Anixa Biosciences, Inc. has a 52-week low of $2.07 and a 52-week high of $5.00. The stock has a market cap of $97.24 million, a P/E ratio of -7.76 and a beta of 0.90. The firm has a 50 day simple moving average of $2.77 and a two-hundred day simple moving average of $3.04.

Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last released its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. On average, equities analysts expect that Anixa Biosciences, Inc. will post -0.46 EPS for the current year.

Analyst Ratings Changes

ANIX has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Wednesday.

Get Our Latest Stock Analysis on ANIX

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences during the third quarter worth $34,000. Tyler Stone Wealth Management grew its holdings in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the last quarter. Westside Investment Management Inc. lifted its holdings in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its position in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after purchasing an additional 23,800 shares during the period. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

See Also